{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:14:31Z","timestamp":1790802871339,"version":"4.1.0"},"reference-count":148,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2019,12,4]]},"abstract":"<jats:sec><jats:title\/><jats:p>Incretin contains two peptides named glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Drug therapy using incretin has become a new strategy for diabetic treatments due to its significant effects on improving insulin receptors and promoting insulinotropic secretion. Considering the fact that diabetes millitus is a key risk factor for almost all age-related diseases, the extensive protective roles of incretin in chronic diseases have received great attention. Based on the evidence from animal experiments, where incretin can protect against the pathophysiological processes of neurodegenerative diseases, clinical trials for the treatments of Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD) patients are currently ongoing. Moreover, the protective effect of incretin on heart has been observed in cardiac myocytes, smooth muscle cells and endothelial cells of vessels. Meanwhile, incretin can also inhibit the proliferation of aortic vascular smooth muscle cells, which can induce atherosclerogenesis. Incretin is also beneficial for diabetic microvascular complications, including nephropathy, retinopathy and gastric ulcer, as well as the hepatic-related diseases such as NAFLD and NASH. Besides, the anti-tumor properties of incretin have been proven in diverse cancers including ovarian cancer, pancreas cancer, prostate cancer and breast cancer.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1567201816666191010145029","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T14:59:37Z","timestamp":1571065177000},"page":"793-806","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Protective Effects of Incretin Against Age-Related Diseases"],"prefix":"10.2174","volume":"16","author":[{"given":"Di","family":"Zhang","sequence":"first","affiliation":[{"name":"Chemistry Department, Shanxi Medical University, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Ma","sequence":"additional","affiliation":[{"name":"Second Hospital, Shanxi Medical University, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueze","family":"Liu","sequence":"additional","affiliation":[{"name":"Second Hospital, Shanxi Medical University, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.12659\/MSMBR.891278","volume":"20","author":"Wang F.","year":"2014","unstructured":"Wang F.; Guo X.; Shen X.; Kream R.M.; Mantione K.J.; Stefano G.B.; Vascular dysfunction associated with type 2 diabetes and Alzheimer\u2019s disease: A potential etiological linkage. Med Sci Monit Basic Res 2014,20,118-129","journal-title":"Med Sci Monit Basic Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ebiom.2018.08.026","volume":"35","author":"James L.M.","year":"2018","unstructured":"James L.M.; Dolan S.; Leuthold A.C.; Engdahl B.E.; Georgopoulos A.; Georgopoulos A.P.; The effects of human leukocyte antigen DRB1*13 and apolipoprotein E on age-related variability of synchronous neural interactions in healthy women. EBioMedicine 2018,35,288-294","journal-title":"EBioMedicine"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.gde.2014.06.003","volume":"26","author":"Orozco-Solis R.","year":"2014","unstructured":"Orozco-Solis R.; Sassone-Corsi P.; Circadian clock: Linking epigenetics to aging. Curr Opin Genet Dev 2014,26,66-72","journal-title":"Curr Opin Genet Dev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2337\/db11-1300","volume":"61","author":"Barzilai N.","year":"2012","unstructured":"Barzilai N.; Huffman D.M.; Muzumdar R.H.; Bartke A.; The critical role of metabolic pathways in aging. Diabetes 2012,61(6),1315-1322","journal-title":"Diabetes"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/NHA-160007","volume":"4","author":"Brewer R.A.","year":"2016","unstructured":"Brewer R.A.; Gibbs V.K.; Smith D.L.; Targeting glucose metabolism for healthy aging. Nutr Healthy Aging 2016,4(1),31-46","journal-title":"Nutr Healthy Aging"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1515\/revneuro-2016-0018","volume":"27","author":"Li Y.","year":"2016","unstructured":"Li Y.; Li L.; H\u00f6lscher C.; Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Rev Neurosci 2016,27(7),689-711","journal-title":"Rev Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.4239\/wjd.v6.i15.1285","volume":"6","author":"Irwin N.","year":"2015","unstructured":"Irwin N.; Flatt P.R.; New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J Diabetes 2015,6(15),1285-1295","journal-title":"World J Diabetes"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2337\/db10-1790","volume":"60","author":"Kielgast U.","year":"2011","unstructured":"Kielgast U.; Holst J.J.; Madsbad S.; Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual \u03b2-cell function. Diabetes 2011,60(5),1599-1607","journal-title":"Diabetes"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.rinphs.2012.09.001","volume":"2","author":"Selis F.","year":"2012","unstructured":"Selis F.; Schrepfer R.; Sanna R.; Scaramuzza S.; Tonon G.; Dedoni S.; Onali P.; Orsini G.; Genovese S.; Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes. Results Pharma Sci 2012,2,58-65","journal-title":"Results Pharma Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.116.305665","volume":"116","author":"Zhong J.","year":"2015","unstructured":"Zhong J.; Maiseyeu A.; Davis S.N.; Rajagopalan S.; DPP4 in cardiometabolic disease: Recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 2015,116(8),1491-1504","journal-title":"Circ Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.neurobiolaging.2008.08.023","volume":"31","author":"H\u00f6lscher C.","year":"2010","unstructured":"H\u00f6lscher C.; Li L.; New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer\u2019s disease? Neurobiol Aging 2010,31(9),1495-1502","journal-title":"Neurobiol Aging"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","volume":"136","author":"H\u00f6lscher C.","year":"2018","unstructured":"H\u00f6lscher C.; Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models. Neuropharmacology 2018,136(Pt B),251-259","journal-title":"Neuropharmacology"},{"key":"ref=13","first-page":"3575","volume":"85","author":"Deacon C.F.","year":"2000","unstructured":"Deacon C.F.; Nauck M.A.; Meier J.; H\u00fccking K.; Holst J.J.; Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000,85(10),3575-3581","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.biopha.2017.10.071","volume":"97","author":"Srivastava S.","year":"2018","unstructured":"Srivastava S.; Shree P.; Pandey H.; Tripathi Y.B.; Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis. Biomed Pharmacother 2018,97,330-338","journal-title":"Biomed Pharmacother"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"Baggio L.L.","year":"2007","unstructured":"Baggio L.L.; Drucker D.J.; Biology of incretins: GLP-1 and GIP. Gastroenterology 2007,132(6),2131-2157","journal-title":"Gastroenterology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1210\/me.15.9.1559","volume":"15","author":"Tr\u00fcmper A.","year":"2001","unstructured":"Tr\u00fcmper A.; Tr\u00fcmper K.; Trusheim H.; Arnold R.; G\u00f6ke B.; H\u00f6rsch D.; Glucose-dependent insulinotropic polypeptide is a growth factor for \u03b2 (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001,15(9),1559-1570","journal-title":"Mol Endocrinol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1677\/joe.0.1740233","volume":"174","author":"Tr\u00fcmper A.","year":"2002","unstructured":"Tr\u00fcmper A.; Tr\u00fcmper K.; H\u00f6rsch D.; Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in \u03b2(INS-1)-cells. J Endocrinol 2002,174(2),233-246","journal-title":"J Endocrinol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1515\/BC.2006.118","volume":"387","author":"Marenah L.","year":"2006","unstructured":"Marenah L.; McCluskey J.T.; Abdel-Wahab Y.H.; O\u2019Harte F.P.; McClenaghan N.H.; Flatt P.R.; A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biol Chem 2006,387(7),941-947","journal-title":"Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.12065","volume":"4","author":"Seino Y.","year":"2013","unstructured":"Seino Y.; Yabe D.; Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013,4(2),108-130","journal-title":"J Diabetes Investig"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.peptides.2017.11.021","volume":"100","author":"Gasbjerg L.S.","year":"2018","unstructured":"Gasbjerg L.S.; Gabe M.B.N.; Hartmann B.; Christensen M.B.; Knop F.K.; Holst J.J.; Rosenkilde M.M.; Glucose-dependent Insulinotropic Polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides 2018,100,173-181","journal-title":"Peptides"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.2337\/db17-0480","volume":"66","author":"Asmar M.","year":"2017","unstructured":"Asmar M.; Asmar A.; Simonsen L.; Gasbjerg L.S.; Sparre-Ulrich A.H.; Rosenkilde M.M.; Hartmann B.; Dela F.; Holst J.J.; B\u00fclow J.; The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor. Diabetes 2017,66(9),2363-2371","journal-title":"Diabetes"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"E2325","DOI":"10.1210\/jc.2014-2547","volume":"99","author":"Nissen A.","year":"2014","unstructured":"Nissen A.; Christensen M.; Knop F.K.; Vilsb\u00f8ll T.; Holst J.J.; Hartmann B.; Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab 2014,99(11),E2325-E2329","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.coph.2006.08.003","volume":"6","author":"Combettes M.M.","year":"2006","unstructured":"Combettes M.M.; GLP-1 and type 2 diabetes: Physiology and new clinical advances. Curr Opin Pharmacol 2006,6(6),598-605","journal-title":"Curr Opin Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/1440-1681.12455","volume":"42","author":"Chen X.W.","year":"2015","unstructured":"Chen X.W.; He Z.X.; Zhou Z.W.; Yang T.; Zhang X.; Yang Y.X.; Duan W.; Zhou S.F.; Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol 2015,42(10),999-1024","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","volume":"21","author":"Finan B.","year":"2015","unstructured":"Finan B.; Yang B.; Ottaway N.; Smiley D.L.; Ma T.; Clemmensen C.; Chabenne J.; Zhang L.; Habegger K.M.; Fischer K.; Campbell J.E.; Sandoval D.; Seeley R.J.; Bleicher K.; Uhles S.; Riboulet W.; Funk J.; Hertel C.; Belli S.; Sebokova E.; Conde-Knape K.; Konkar A.; Drucker D.J.; Gelfanov V.; Pfluger P.T.; M\u00fcller T.D.; Perez-Tilve D.; DiMarchi R.D.; Tsch\u00f6p M.H.; A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015,21(1),27-36","journal-title":"Nat Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2337\/dc07-1572","volume":"31","author":"Hoerger T.J.","year":"2008","unstructured":"Hoerger T.J.; Segel J.E.; Gregg E.W.; Saaddine J.B.; Is glycemic control improving in U.S. adults? Diabetes Care 2008,31(1),81-86","journal-title":"Diabetes Care"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2337\/dc09-1499","volume":"33","author":"Drucker D.J.","year":"2010","unstructured":"Drucker D.J.; Sherman S.I.; Gorelick F.S.; Bergenstal R.M.; Sherwin R.S.; Buse J.B.; Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits. Diabetes Care 2010,33(2),428-433","journal-title":"Diabetes Care"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pharmthera.2009.06.002","volume":"124","author":"Verspohl E.J.","year":"2009","unstructured":"Verspohl E.J.; Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009,124(1),113-138","journal-title":"Pharmacol Ther"},{"key":"ref=29","year":"2008","unstructured":"Clinical practice guidelines for the prevention and management of diabetes in Canada Canadian Diabetes Association2008","journal-title":"Clinical practice guidelines for the prevention and management of diabetes in Canada"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsps.2015.06.009","volume":"25","author":"Al Tulaihi B.","year":"2017","unstructured":"Al Tulaihi B.; Alhabib S.; Uncertainties around incretin-based therapies: A literature review. Saudi Pharm J 2017,25(1),1-7","journal-title":"Saudi Pharm J"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ddr.1195","volume":"53","author":"Parkes D.","year":"2001","unstructured":"Parkes D.; Jodka C.; Smith P.; Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res 2001,53,260-267","journal-title":"Drug Dev Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/138920309787315158","volume":"10","author":"Knop F.K.","year":"2009","unstructured":"Knop F.K.; Vilsb\u00f8ll T.; Holst J.J.; Incretin-based therapy of type 2 diabetes mellitus. Curr Protein Pept Sci 2009,10(1),46-55","journal-title":"Curr Protein Pept Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsps.2015.06.009","volume":"25","author":"Al Tulaihi B.","year":"2017","unstructured":"Al Tulaihi B.; Alhabib S.; Uncertainties around incretin-based therapies: A literature review. Saudi Pharm J 2017,25(1),1-7","journal-title":"Saudi Pharm J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1463-1326.2010.01325.x","volume":"13","author":"Schweizer A.","year":"2011","unstructured":"Schweizer A.; Dejager S.; Foley J.E.; Shao Q.; Kothny W.; Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population \u226575 years: A pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011,13(1),55-64","journal-title":"Diabetes Obes Metab"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1124\/pr.108.000604","volume":"60","author":"Kim W.","year":"2008","unstructured":"Kim W.; Egan J.M.; The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008,60(4),470-512","journal-title":"Pharmacol Rev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/BST20140016","volume":"42","author":"H\u00f6lscher C.","year":"2014","unstructured":"H\u00f6lscher C.; Insulin, incretins and other growth factors as potential novel treatments for Alzheimer\u2019s and Parkinson\u2019s diseases. Biochem Soc Trans 2014,42(2),593-599","journal-title":"Biochem Soc Trans"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db09-1694","volume":"59","author":"Arakawa M.","year":"2010","unstructured":"Arakawa M.; Mita T.; Azuma K.; Ebato C.; Goto H.; Nomiyama T.; Fujitani Y.; Hirose T.; Kawamori R.; Watada H.; Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010,59(4),1030-1037","journal-title":"Diabetes"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.peptides.2009.06.019","volume":"30","author":"Dozier K.C.","year":"2009","unstructured":"Dozier K.C.; Cureton E.L.; Kwan R.O.; Curran B.; Sadjadi J.; Victorino G.P.; Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 2009,30(9),1735-1741","journal-title":"Peptides"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ejphar.2015.09.024","volume":"765","author":"Solmaz V.","year":"2015","unstructured":"Solmaz V.; \u00c7\u0131nar B.P.; Yi\u011fitt\u00fcrk G.; \u00c7avu\u015fo\u011flu T.; Ta\u015fk\u0131ran D.; Erba\u015f O.; Exenatide reduces TNF-\u03b1 expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur J Pharmacol 2015,765,482-487","journal-title":"Eur J Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103114","volume":"9","author":"Darsalia V.","year":"2014","unstructured":"Darsalia V.; Hua S.; Larsson M.; Mallard C.; Nathanson D.; Nystr\u00f6m T.; Sj\u00f6holm \u00c5.; Johansson M.E.; Patrone C.; Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLoS One 2014,9(8)","journal-title":"PLoS One"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/JOE-09-0132","volume":"202","author":"Kim S.","year":"2009","unstructured":"Kim S.; Moon M.; Park S.; Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease. J Endocrinol 2009,202(3),431-439","journal-title":"J Endocrinol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejphar.2012.12.012","volume":"700","author":"Parthsarathy V.","year":"2013","unstructured":"Parthsarathy V.; H\u00f6lscher C.; The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol 2013,700(1-3),42-50","journal-title":"Eur J Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0806720106","volume":"106","author":"Li Y.","year":"2009","unstructured":"Li Y.; Perry T.; Kindy M.S.; Harvey B.K.; Tweedie D.; Holloway H.W.; Powers K.; Shen H.; Egan J.M.; Sambamurti K.; Brossi A.; Lahiri D.K.; Mattson M.P.; Hoffer B.J.; Wang Y.; Greig N.H.; GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009,106(4),1285-1290","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"McClean P.L.","year":"2011","unstructured":"McClean P.L.; Parthsarathy V.; Faivre E.; H\u00f6lscher C.; The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci 2011,31(17),6587-6594","journal-title":"J Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"T31","DOI":"10.1530\/JOE-13-0221","volume":"221","author":"H\u00f6lscher C.","year":"2014","unstructured":"H\u00f6lscher C.; Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014,221(1),T31-T41","journal-title":"J Endocrinol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"Aviles-Olmos I.","year":"2013","unstructured":"Aviles-Olmos I.; Dickson J.; Kefalopoulou Z.; Djamshidian A.; Ell P.; Soderlund T.; Whitton P.; Wyse R.; Isaacs T.; Lees A.; Limousin P.; Foltynie T.; Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest 2013,123(6),2730-2736","journal-title":"J Clin Invest"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","volume":"4","author":"Aviles-Olmos I.","year":"2014","unstructured":"Aviles-Olmos I.; Dickson J.; Kefalopoulou Z.; Djamshidian A.; Kahan J.; Ell P.; Whitton P.; Wyse R.; Isaacs T.; Lees A.; Limousin P.; Foltynie T.; Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease. J Parkinsons Dis 2014,4(3),337-344","journal-title":"J Parkinsons Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"Gejl M.","year":"2016","unstructured":"Gejl M.; Gjedde A.; Egefjord L.; M\u00f8ller A.; Hansen S.B.; Vang K.; Rodell A.; Br\u00e6ndgaard H.; Gottrup H.; Schacht A.; M\u00f8ller N.; Brock B.; Rungby J.; Alzheimer\u2019s disease, six-month treatment with GLP-1analogue prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 2016,8,108-117","journal-title":"Front Aging Neurosci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jalz.2013.12.009","volume":"10","author":"H\u00f6lscher C.","year":"2014","unstructured":"H\u00f6lscher C.; The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer\u2019s disease. Alzheimers Dement 2014,10(1)(Suppl.),S47-S54","journal-title":"Alzheimers Dement"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1515\/revneuro-2015-0021","volume":"27","author":"Ji C.","year":"2016","unstructured":"Ji C.; Xue G.F.; Li G.; Li D.; H\u00f6lscher C.; Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer\u2019s disease. Rev Neurosci 2016,27(1),61-70","journal-title":"Rev Neurosci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","volume":"15","author":"Long-Smith C.M.","year":"2013","unstructured":"Long-Smith C.M.; Manning S.; McClean P.L.; Coakley M.F.; O\u2019Halloran D.J.; Holscher C.; O\u2019Neill C.; The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 plaque and glial pathology in a mouse model of Alzheimer\u2019s disease. Neuromolecular Med 2013,15(1),102-114","journal-title":"Neuromolecular Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","volume":"86C","author":"McClean P.L.","year":"2014","unstructured":"McClean P.L.; Holscher C.; Lixisenatide shows neuroprotective effects in a mouse model of AD. Neuropharmacology 2014,86C,241-258","journal-title":"Neuropharmacology"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/aps.2010.38","volume":"31","author":"Li H.","year":"2010","unstructured":"Li H.; Lam A.; Xu A.M.; Lam K.S.; Chung S.K.; High dosage of Exendin-4 increased early insulin secretion in differentiated beta cells from mouse embryonic stem cells. Acta Pharmacol Sin 2010,31(5),570-577","journal-title":"Acta Pharmacol Sin"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.neurobiolaging.2010.02.014","volume":"33","author":"Gengler S.","year":"2012","unstructured":"Gengler S.; McClean P.L.; McCurtin R.; Gault V.A.; H\u00f6lscher C.; Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP\/PS1 mice. Neurobiol Aging 2012,33(2),265-276","journal-title":"Neurobiol Aging"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuint.2015.04.002","volume":"89","author":"Zhang Y.","year":"2015","unstructured":"Zhang Y.; Yin F.; Liu J.; Liu Z.; Guo L.; Xia Z.; Zidichouski J.; Geniposide attenuates insulin-deficiency-induced acceleration of \u03b2-amyloidosis in an APP\/PS1 transgenic model of Alzheimer\u2019s disease. Neurochem Int 2015,89,7-16","journal-title":"Neurochem Int"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1042\/BST0390891","volume":"39","author":"H\u00f6lscher C.","year":"2011","unstructured":"H\u00f6lscher C.; Diabetes as a risk factor for Alzheimer\u2019s disease: insulin signalling impairment in the brain as an alternative model of Alzheimer\u2019s disease. Biochem Soc Trans 2011,39(4),891-897","journal-title":"Biochem Soc Trans"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","volume":"133","author":"Feng P.","year":"2018","unstructured":"Feng P.; Zhang X.; Li D.; Ji C.; Yuan Z.; Wang R.; Xue G.; Li G.; H\u00f6lscher C.; Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology 2018,133,385-394","journal-title":"Neuropharmacology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","volume":"86","author":"Bertilsson G.","year":"2008","unstructured":"Bertilsson G.; Patrone C.; Zachrisson O.; Andersson A.; Dannaeus K.; Heidrich J.; Kortesmaa J.; Mercer A.; Nielsen E.; R\u00f6nnholm H.; Wikstr\u00f6m L.; Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease. J Neurosci Res 2008,86(2),326-338","journal-title":"J Neurosci Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.npep.2012.07.004","volume":"46","author":"Rampersaud N.","year":"2012","unstructured":"Rampersaud N.; Harkavyi A.; Giordano G.; Lever R.; Whitton J.; Whitton P.S.; Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson\u2019s disease with combined noradrenergic and serotonergic lesions. Neuropeptides 2012,46(5),183-193","journal-title":"Neuropeptides"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.npep.2012.07.004","volume":"46","author":"Rampersaud N.","year":"2012","unstructured":"Rampersaud N.; Harkavyi A.; Giordano G.; Lever R.; Whitton J.; Whitton P.S.; Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson\u2019s disease with combined noradrenergic and serotonergic lesions. Neuropeptides 2012,46(5),183-193","journal-title":"Neuropeptides"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbr.2015.07.021","volume":"293","author":"Zhang Y.","year":"2015","unstructured":"Zhang Y.; Chen Y.; Li L.; H\u00f6lscher C.; Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson\u2019s disease mouse model. Behav Brain Res 2015,293,107-113","journal-title":"Behav Brain Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","volume":"303","author":"Liu W.","year":"2015","unstructured":"Liu W.; Jalewa J.; Sharma M.; Li G.; Li L.; H\u00f6lscher C.; Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Neuroscience 2015,303,42-50","journal-title":"Neuroscience"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejphar.2015.09.029","volume":"768","author":"Chen Y.","year":"2015","unstructured":"Chen Y.; Zhang Y.; Li L.; H\u00f6lscher C.; Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson\u2019s disease. Eur J Pharmacol 2015,768,21-27","journal-title":"Eur J Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"Athauda D.","year":"2017","unstructured":"Athauda D.; Maclagan K.; Skene S.S.; Bajwa-Joseph M.; Letchford D.; Chowdhury K.; Hibbert S.; Budnik N.; Zampedri L.; Dickson J.; Li Y.; Aviles-Olmos I.; Warner T.T.; Limousin P.; Lees A.J.; Greig N.H.; Tebbs S.; Foltynie T.; Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial. Lancet 2017,390(10103),1664-1675","journal-title":"Lancet"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/17482960902822960","volume":"11","author":"Pradat P.F.","year":"2010","unstructured":"Pradat P.F.; Bruneteau G.; Gordon P.H.; Dupuis L.; Bonnefont-Rousselot D.; Simon D.; Salachas F.; Corcia P.; Frochot V.; Lacorte J.M.; Jardel C.; Coussieu C.; Le Forestier N.; Lacomblez L.; Loeffler J.P.; Meininger V.; Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010,11(1-2),166-171","journal-title":"Amyotroph Lateral Scler"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1210\/jcem-63-1-41","volume":"63","author":"Harris M.D.","year":"1986","unstructured":"Harris M.D.; Davidson M.B.; Rosenberg C.S.; Insulin antagonism is not a primary abnormality of ALS but is related to disease severity. J Clin Endocrinol Metab 1986,63,41-46","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/1756-0500-7-171","volume":"7","author":"Lekoubou A.","year":"2014","unstructured":"Lekoubou A.; Matsha T.E.; Sobngwi E.; Kengne A.P.; Effects of diabetes mellitus on amyotrophic lateral sclerosis: A systematic review. BMC Res Notes 2014,7,171-178","journal-title":"BMC Res Notes"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032008","volume":"7","author":"Li Y.","year":"2012","unstructured":"Li Y.; Chigurupati S.; Holloway H.W.; Mughal M.; Tweedie D.; Bruestle D.A.; Mattson M.P.; Wang Y.; Harvey B.K.; Ray B.; Lahiri D.K.; Greig N.H.; Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 2012,7(2)","journal-title":"PLoS One"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neulet.2010.05.017","volume":"479","author":"Lim J.G.","year":"2010","unstructured":"Lim J.G.; Lee J.J.; Park S.H.; Park J.H.; Kim S.J.; Cho H.C.; Baek W.K.; Kim D.K.; Song D.K.; Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement. Neurosci Lett 2010,479(1),13-17","journal-title":"Neurosci Lett"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10571-012-9900-9","volume":"33","author":"Sun H.","year":"2013","unstructured":"Sun H.; Knippenberg S.; Thau N.; Ragancokova D.; K\u00f6rner S.; Huang D.; Dengler R.; D\u00f6hler K.; Petri S.; Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol 2013,33(3),347-357","journal-title":"Cell Mol Neurobiol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1515\/REVNEURO.2007.18.3-4.223","volume":"18","author":"Aziz N.A.","year":"2007","unstructured":"Aziz N.A.; Swaab D.F.; Pijl H.; Roos R.A.; Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington\u2019s disease: Clinical consequences and therapeutic implications. Rev Neurosci 2007,18(3-4),223-251","journal-title":"Rev Neurosci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/jnnp.2009.191833","volume":"81","author":"Aziz N.A.","year":"2010","unstructured":"Aziz N.A.; Pijl H.; Fr\u00f6lich M.; Snel M.; Streefland T.C.; Roelfsema F.; Roos R.A.; Systemic energy homeostasis in Huntington\u2019s disease patients. J Neurol Neurosurg Psychiatry 2010,81(11),1233-1237","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3233\/JAD-131847","volume":"40","author":"Hu Y.","year":"2014","unstructured":"Hu Y.; Liang J.; High, Yu S High High prevalence of diabetes mellitus in a five-generation Chinese family with Huntingtong\u2019s disease. J Alzheimers Dis 2014,40,863-868","journal-title":"J Alzheimers Dis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2337\/db08-0799","volume":"58","author":"Martin B.","year":"2009","unstructured":"Martin B.; Golden E.; Carlson O.D.; Pistell P.; Zhou J.; Kim W.; Frank B.P.; Thomas S.; Chadwick W.A.; Greig N.H.; Bates G.P.; Sathasivam K.; Bernier M.; Maudsley S.; Mattson M.P.; Egan J.M.; Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington\u2019s disease. Diabetes 2009,58(2),318-328","journal-title":"Diabetes"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"31766","DOI":"10.1074\/jbc.M112.387316","volume":"287","author":"Martin B.","year":"2012","unstructured":"Martin B.; Chadwick W.; Cong W.N.; Pantaleo N.; Daimon C.M.; Golden E.J.; Becker K.G.; Wood W.H.; Carlson O.D.; Egan J.M.; Maudsley S.; Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy. J Biol Chem 2012,287(38),31766-31782","journal-title":"J Biol Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/en.2017-00461","volume":"158","author":"Iwaya C.","year":"2017","unstructured":"Iwaya C.; Nomiyama T.; Komatsu S.; Kawanami T.; Tsutsumi Y.; Hamaguchi Y.; Horikawa T.; Yoshinaga Y.; Yamashita S.; Tanaka T.; Terawaki Y.; Tanabe M.; Nabeshima K.; Iwasaki A.; Yanase T.; Exendin-4, a glucagon like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting GF-\u03baB activation. Endocrinology 2017,158(12),4218-4232","journal-title":"Endocrinology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11892-014-0483-3","volume":"14","author":"Avogaro A.","year":"2014","unstructured":"Avogaro A.; Vigili de Kreutzenberg S.; Fadini G.P.; Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. Curr Diab Rep 2014,14(5),483-493","journal-title":"Curr Diab Rep"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1172\/JCI0215595","volume":"110","author":"Yamamoto H.","year":"2002","unstructured":"Yamamoto H.; Lee C.E.; Marcus J.N.; Williams T.D.; Overton J.M.; Lopez M.E.; Hollenberg A.N.; Baggio L.; Saper C.B.; Drucker D.J.; Elmquist J.K.; Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002,110(1),43-52","journal-title":"J Clin Invest"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/jpet.104.073890","volume":"312","author":"Nikolaidis L.A.","year":"2005","unstructured":"Nikolaidis L.A.; Doverspike A.; Hentosz T.; Zourelias L.; Shen Y.T.; Elahi D.; Shannon R.P.; Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005,312(1),303-308","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.116.305665","volume":"116","author":"Zhong J.","year":"2015","unstructured":"Zhong J.; Maiseyeu A.; Davis S.N.; Rajagopalan S.; DPP4 in cardiometabolic disease: Recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 2015,116(8),1491-1504","journal-title":"Circ Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"Mulvihill E.E.","year":"2014","unstructured":"Mulvihill E.E.; Drucker D.J.; Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 2014,35(6),992-1019","journal-title":"Endocr Rev"},{"key":"ref=82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182422","volume":"12","author":"Suda M.","year":"2017","unstructured":"Suda M.; Shimizu I.; Yoshida Y.; Hayashi Y.; Ikegami R.; Katsuumi G.; Wakasugi T.; Yoshida Y.; Okuda S.; Soga T.; Minamino T.; Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2\/EGR-1 pathway. PLoS One 2017,12(8)","journal-title":"PLoS One"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/CIRCHEARTFAILURE.112.000057","volume":"6","author":"dos Santos L.","year":"2013","unstructured":"dos Santos L.; Salles T.A.; Arruda-Junior D.F.; Campos L.C.; Pereira A.C.; Barreto A.L.; Antonio E.L.; Mansur A.J.; Tucci P.J.; Krieger J.E.; Girardi A.C.; Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail 2013,6(5),1029-1038","journal-title":"Circ Heart Fail"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.115.003046","volume":"5","author":"Jeong E.M.","year":"2016","unstructured":"Jeong E.M.; Chung J.; Liu H.; Go Y.; Gladstein S.; Farzaneh-Far A.; Lewandowski E.D.; Dudley S.C.; Role of mitochondrial oxidative stress in glucose tolerance, insulin resistance, and cardiac diastolic dysfunction. J Am Heart Assoc 2016,5(5),1-17","journal-title":"J Am Heart Assoc"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2011.12.006","volume":"15","author":"Shimizu I.","year":"2012","unstructured":"Shimizu I.; Yoshida Y.; Katsuno T.; Tateno K.; Okada S.; Moriya J.; Yokoyama M.; Nojima A.; Ito T.; Zechner R.; Komuro I.; Kobayashi Y.; Minamino T.; p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab 2012,15(1),51-64","journal-title":"Cell Metab"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"H584","DOI":"10.1152\/ajpheart.00103.2017","volume":"313","author":"Warren J.S.","year":"2017","unstructured":"Warren J.S.; Oka S.I.; Zablocki, D Metabolic reprogramming via PPAR\u03b1 signaling in cardiac hypertrophy and failure: From metabolomics to epigenetics. Am J Phy Siol Heart Physiol 2017,313,H584-H596","journal-title":"Am J Phy Siol Heart Physiol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","volume":"113","author":"Doenst T.","year":"2013","unstructured":"Doenst T.; Nguyen T.D.; Abel E.D.; Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res 2013,113(6),709-724","journal-title":"Circ Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.metabol.2014.04.002","volume":"63","author":"Bostick B.","year":"2014","unstructured":"Bostick B.; Habibi J.; Ma L.; Aroor A.; Rehmer N.; Hayden M.R.; Sowers J.R.; Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of western diet induced obesity. Metabolism 2014,63(8),1000-1011","journal-title":"Metabolism"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","volume":"385","author":"Gilbert R.E.","year":"2015","unstructured":"Gilbert R.E.; Krum H.; Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. Lancet 2015,385(9982),2107-2117","journal-title":"Lancet"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"Zannad F.","year":"2015","unstructured":"Zannad F.; Cannon C.P.; Cushman W.C.; Bakris G.L.; Menon V.; Perez A.T.; Fleck P.R.; Mehta C.R.; Kupfer S.; Wilson C.; Lam H.; White W.B.; Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet EXAMINE Investigators2015,385(9982),2067-2076","journal-title":"Lancet"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","volume":"374","author":"Filion K.B.","year":"2016","unstructured":"Filion K.B.; Azoulay L.; Platt R.W.; Dahl M.; Dormuth C.R.; Clemens K.K.; Hu N.; Paterson J.M.; Targownik L.; Turin T.C.; Udell J.A.; Ernst P.; A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med CNODES investigators2016,374(12),1145-1154","journal-title":"N Engl J Med"},{"key":"ref=92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182422","volume":"12","author":"Suda M.","year":"2017","unstructured":"Suda M.; Shimizu I.; Yoshida Y.; Hayashi Y.; Ikegami R.; Katsuumi G.; Wakasugi T.; Yoshida Y.; Okuda S.; Soga T.; Minamino T.; Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2\/EGR-1 pathway. PLoS One 2017,12(8)","journal-title":"PLoS One"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbrc.2014.10.029","volume":"454","author":"Morita M.","year":"2014","unstructured":"Morita M.; Hayashi T.; Ochiai M.; Maeda M.; Yamaguchi T.; Ina K.; Kuzuya M.; Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances NO bioavailability. Biochem Biophys Res Commun 2014,454(1),53-57","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"e002424","DOI":"10.1161\/CIRCHEARTFAILURE.115.002424","volume":"9","author":"Baumgardt S.L.","year":"2016","unstructured":"Baumgardt S.L.; Paterson M.; Leucker T.M.; Fang J.; Zhang D.X.; Bosnjak Z.J.; Warltier D.C.; Kersten J.R.; Ge Z.D.; Chronic co-administration of sepiapterin and L-citrulline ameliorates diabetic cardiomyopathy and myocardial ischemia\/reperfusion injury in obese type 2 diabetic mice. Circ Heart Fail 2016,9(1),e002424-e002431","journal-title":"Circ Heart Fail"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.yjmcc.2007.03.899","volume":"42","author":"Lygate C.A.","year":"2007","unstructured":"Lygate C.A.; Fischer A.; Sebag-Montefiore L.; Wallis J.; ten Hove M.; Neubauer S.; The creatine kinase energy transport system in the failing mouse heart. J Mol Cell Cardiol 2007,42(6),1129-1136","journal-title":"J Mol Cell Cardiol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cardfail.2007.10.020","volume":"14","author":"Lindbom M.","year":"2008","unstructured":"Lindbom M.; Ramunddal T.; Camejo G.; Waagstein F.; Omerovic E.; In vivo effects of myocardial creatine depletion on left ventricular function morphology and lipid metabolism: Study in a mouse model. J Card Fail 2008,14(2),161-166","journal-title":"J Card Fail"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/cvr\/cvs272","volume":"96","author":"Lygate C.A.","year":"2012","unstructured":"Lygate C.A.; Bohl S.; ten Hove M.; Faller K.M.; Ostrowski P.J.; Zervou S.; Medway D.J.; Aksentijevic D.; Sebag-Montefiore L.; Wallis J.; Clarke K.; Watkins H.; Schneider J.E.; Neubauer S.; Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. Cardiovasc Res 2012,96(3),466-475","journal-title":"Cardiovasc Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1536\/ihj.46.289","volume":"46","author":"Yajima S.","year":"2005","unstructured":"Yajima S.; Ishikawa M.; Kubota T.; Moroi M.; Sugi K.; Namiki A.; Intramyocardial injection of fibroblast growth factor-2 plus heparin suppresses cardiac failure progression in rats with hypertensive heart disease. Int Heart J 2005,46(2),289-301","journal-title":"Int Heart J"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db09-1694","volume":"59","author":"Arakawa M.","year":"2010","unstructured":"Arakawa M.; Mita T.; Azuma K.; Ebato C.; Goto H.; Nomiyama T.; Fujitani Y.; Hirose T.; Kawamori R.; Watada H.; Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010,59(4),1030-1037","journal-title":"Diabetes"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2010.12.131","volume":"405","author":"Goto H.","year":"2011","unstructured":"Goto H.; Nomiyama T.; Mita T.; Yasunari E.; Azuma K.; Komiya K.; Arakawa M.; Jin W.L.; Kanazawa A.; Kawamori R.; Fujitani Y.; Hirose T.; Watada H.; Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011,405(1),79-84","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3803\/EnM.2017.32.3.316","volume":"32","author":"Kang Y.M.","year":"2017","unstructured":"Kang Y.M.; Jung C.H.; Effects of incretin-based therapies on diabetic microvascular complications. Endocrinol Metab (Seoul) 2017,32(3),316-325","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref=102","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/816164","author":"Silva J\u00fanior W.S.","year":"2015","unstructured":"Silva J\u00fanior W.S.; Godoy-Matos A.F.; Kraemer-Aguiar L.G.; Dipeptidyl peptidase 4: A new link between diabetes mellitus and atherosclerosis? BioMed Res Int 2015","journal-title":"BioMed Res Int"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-015-0176-5","volume":"14","author":"Yamagishi S.","year":"2015","unstructured":"Yamagishi S.; Fukami K.; Matsui T.; Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol 2015,14,2-13","journal-title":"Cardiovasc Diabetol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"H477","DOI":"10.1152\/ajpheart.00209.2014","volume":"307","author":"Aroor A.R.","year":"2014","unstructured":"Aroor A.R.; Sowers J.R.; Jia G.; DeMarco V.G.; Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol 2014,307(4),H477-H492","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"E1223","DOI":"10.3390\/ijms17081223","volume":"17","author":"Kawanami D.","year":"2016","unstructured":"Kawanami D.; Matoba K.; Sango K.; Utsunomiya K.; Incretin-based therapies for diabetic complications: Basic mechanisms and clinical evidence. Int J Mol Sci 2016,17(8),E1223-E1239","journal-title":"Int J Mol Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","volume":"53","author":"Hadjiyanni I.","year":"2010","unstructured":"Hadjiyanni I.; Siminovitch K.A.; Danska J.S.; Drucker D.J.; Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 2010,53(4),730-740","journal-title":"Diabetologia"},{"key":"ref=107","first-page":"B4634","volume":"60","author":"Hansen L.B.","year":"2013","unstructured":"Hansen L.B.; GLP-2 and mesenteric blood flow. Dan Med J 2013,60(5),B4634","journal-title":"Dan Med J"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fphys.2012.00128","volume":"3","author":"Harrison D.G.","year":"2012","unstructured":"Harrison D.G.; Marvar P.J.; Titze J.M.; Vascular inflammatory cells in hypertension. Front Physiol 2012,3,128-135","journal-title":"Front Physiol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2337\/db11-1824","volume":"61","author":"Mima A.","year":"2012","unstructured":"Mima A.; Hiraoka-Yamomoto J.; Li Q.; Kitada M.; Li C.; Geraldes P.; Matsumoto M.; Mizutani K.; Park K.; Cahill C.; Nishikawa S.; Rask-Madsen C.; King G.L.; Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC\u03b2 activation in diabetes. Diabetes 2012,61(11),2967-2979","journal-title":"Diabetes"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.metabol.2011.01.010","volume":"60","author":"Ishibashi Y.","year":"2011","unstructured":"Ishibashi Y.; Nishino Y.; Matsui T.; Takeuchi M.; Yamagishi S.; Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011,60(9),1271-1277","journal-title":"Metabolism"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","volume":"61","author":"Hendarto H.","year":"2012","unstructured":"Hendarto H.; Inoguchi T.; Maeda Y.; Ikeda N.; Zheng J.; Takei R.; Yokomizo H.; Hirata E.; Sonoda N.; Takayanagi R.; GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012,61(10),1422-1434","journal-title":"Metabolism"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3892\/ijmm.2016.2711","volume":"38","author":"Zhang Z.","year":"2016","unstructured":"Zhang Z.; Yang L.; Lei L.; Chen R.; Chen H.; Zhang H.; Glucagon-like peptide-1 attenuates advanced oxidation protein product-mediated damage in islet microvascular endothelial cells partly through the RAGE pathway. Int J Mol Med 2016,38(4),1161-1169","journal-title":"Int J Mol Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000337929","volume":"35","author":"Zhang H.","year":"2012","unstructured":"Zhang H.; Zhang X.; Hu C.; Lu W.; Exenatide reduces urinary transforming growth factor-\u03b21 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res 2012,35(6),483-488","journal-title":"Kidney Blood Press Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/dme.12594","volume":"32","author":"von Scholten B.J.","year":"2015","unstructured":"von Scholten B.J.; Lajer M.; Goetze J.P.; Persson F.; Rossing P.; Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med 2015,32(3),343-352","journal-title":"Diabet Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jdiacomp.2015.04.004","volume":"29","author":"von Scholten B.J.","year":"2015","unstructured":"von Scholten B.J.; Hansen T.W.; Goetze J.P.; Persson F.; Rossing P.; Glucagon-like peptide 1 receptor agonist (GLP-1 RA): Long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications 2015,29(5),670-674","journal-title":"J Diabetes Complications"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.bbrc.2013.12.049","volume":"443","author":"Kodera R.","year":"2014","unstructured":"Kodera R.; Shikata K.; Takatsuka T.; DPP-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun 2014,443,828-833","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1507\/endocrj.K10E-382","volume":"58","author":"Hattori S.","year":"2011","unstructured":"Hattori S.; Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011,58(1),69-73","journal-title":"Endocr J"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1507\/endocrj.EJ13-0305","volume":"61","author":"Fujita H.","year":"2014","unstructured":"Fujita H.; Taniai H.; Murayama H.; Ohshiro H.; Hayashi H.; Sato S.; Kikuchi N.; Komatsu T.; Komatsu K.; Komatsu K.; Narita T.; Yamada Y.; DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1\u03b1 in type 2 diabetic patients with incipient nephropathy. Endocr J 2014,61(2),159-166","journal-title":"Endocr J"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40256-013-0043-2","volume":"13","author":"Tani S.","year":"2013","unstructured":"Tani S.; Nagao K.; Hirayama A.; Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: A pilot study. Am J Cardiovasc Drugs 2013,13(6),443-450","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.2337\/dc13-0323","volume":"36","author":"Groop P.H.","year":"2013","unstructured":"Groop P.H.; Cooper M.E.; Perkovic V.; Emser A.; Woerle H.J.; von Eynatten M.; Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013,36(11),3460-3468","journal-title":"Diabetes Care"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","volume":"65","author":"Hern\u00e1ndez C.","year":"2016","unstructured":"Hern\u00e1ndez C.; Bogdanov P.; Corraliza L.; Garc\u00eda-Ram\u00edrez M.; Sol\u00e0-Adell C.; Arranz J.A.; Arroba A.I.; Valverde A.M.; Sim\u00f3 R.; Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 2016,65(1),172-187","journal-title":"Diabetes"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.exer.2014.05.004","volume":"127","author":"Fan Y.","year":"2014","unstructured":"Fan Y.; Liu K.; Wang Q.; Ruan Y.; Ye W.; Zhang Y.; Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res 2014,127,104-116","journal-title":"Exp Eye Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1463-1326.2011.01548.x","volume":"14","author":"Gon\u00e7alves A.","year":"2012","unstructured":"Gon\u00e7alves A.; Leal E.; Paiva A.; Teixeira Lemos E.; Teixeira F.; Ribeiro C.F.; Reis F.; Ambr\u00f3sio A.F.; Fernandes R.; Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 2012,14(5),454-463","journal-title":"Diabetes Obes Metab"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.bbadis.2014.04.013","volume":"1842","author":"Goncalves A","year":"2014","unstructured":"Goncalves A; Marques C; Leal E.; Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Bio\u00acphys Acta 2014,1842,1454-1463","journal-title":"Biochim Bio\u00acphys Acta"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1475-2840-13-19","volume":"13","author":"Ott C.","year":"2014","unstructured":"Ott C.; Raff U.; Schmidt S.; Kistner I.; Friedrich S.; Bramlage P.; Harazny J.M.; Schmieder R.E.; Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol 2014,13,19-27","journal-title":"Cardiovasc Diabetol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"Armstrong M.J.","year":"2016","unstructured":"Armstrong M.J.; Hull D.; Guo K.; Barton D.; Hazlehurst J.M.; Gathercole L.L.; Nasiri M.; Yu J.; Gough S.C.; Newsome P.N.; Tomlinson J.W.; Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016,64(2),399-408","journal-title":"J Hepatol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/dom.13007","volume":"19","author":"Khoo J.","year":"2017","unstructured":"Khoo J.; Hsiang J.; Taneja R.; Law N.M.; Ang T.L.; Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. Diabetes Obes Metab 2017,19(12),1814-1817","journal-title":"Diabetes Obes Metab"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-017-02866-y","volume":"7","author":"de Mesquita F.C.","year":"2017","unstructured":"de Mesquita F.C.; Guix\u00e9-Muntet S.; Fern\u00e1ndez-Iglesias A.; Maeso-D\u00edaz R.; Vila S.; Hide D.; Ortega-Ribera M.; Rosa J.L.; Garc\u00eda-Pag\u00e1n J.C.; Bosch J.; de Oliveira J.R.; Gracia-Sancho J.; Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. Sci Rep 2017,7(1),3255-3264","journal-title":"Sci Rep"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev-med-050913-022228","volume":"66","author":"Iyengar N.M.","year":"2015","unstructured":"Iyengar N.M.; Hudis C.A.; Dannenberg A.J.; Obesity and cancer: Local and systemic mechanisms. Annu Rev Med 2015,66,297-309","journal-title":"Annu Rev Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejmech.2017.09.013","volume":"142","author":"Baldassano S.","year":"2017","unstructured":"Baldassano S.; Accardi G.; Vasto S.; Beta-glucans and cancer: The influence of inflammation and gut peptide. Eur J Med Chem 2017,142,486-492","journal-title":"Eur J Med Chem"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"Reubi J.C.","year":"2003","unstructured":"Reubi J.C.; Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003,24(4),389-427","journal-title":"Endocr Rev"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","volume":"30","author":"Reubi J.C.","year":"2003","unstructured":"Reubi J.C.; Waser B.; Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003,30(5),781-793","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","volume":"48","author":"K\u00f6rner M.","year":"2007","unstructured":"K\u00f6rner M.; St\u00f6ckli M.; Waser B.; Reubi J.C.; GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J Nucl Med 2007,48(5),736-743","journal-title":"J Nucl Med"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1158\/1078-0432.CCR-06-2965","volume":"13","author":"Wicki A.","year":"2007","unstructured":"Wicki A.; Wild D.; Storch D.; Seemayer C.; Gotthardt M.; Behe M.; Kneifel S.; Mihatsch M.J.; Reubi J.C.; M\u00e4cke H.R.; Christofori G.; [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007,13(12),3696-3705","journal-title":"Clin Cancer Res"},{"key":"ref=135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071716","volume":"8","author":"Luciani P.","year":"2013","unstructured":"Luciani P.; Deledda C.; Benvenuti S.; Squecco R.; Cellai I.; Fibbi B.; Marone I.M.; Giuliani C.; Modi G.; Francini F.; Vannelli G.B.; Peri A.; Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells. PLoS One 2013,8(8)","journal-title":"PLoS One"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1210\/en.2011-1201","volume":"152","author":"Koehler J.A.","year":"2011","unstructured":"Koehler J.A.; Kain T.; Drucker D.J.; Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology 2011,152(9),3362-3372","journal-title":"Endocrinology"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","volume":"132","author":"Ligumsky H.","year":"2012","unstructured":"Ligumsky H.; Wolf I.; Israeli S.; Haimsohn M.; Ferber S.; Karasik A.; Kaufman B.; Rubinek T.; The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat 2012,132(2),449-461","journal-title":"Breast Cancer Res Treat"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jdi.12068","volume":"4","author":"Noto H.","year":"2013","unstructured":"Noto H.; Goto A.; Tsujimoto T.; Osame K.; Noda M.; Latest insights into the risk of cancer in diabetes. J Diabetes Investig 2013,4(3),225-232","journal-title":"J Diabetes Investig"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/en.2017-00461","volume":"158","author":"Iwaya C.","year":"2017","unstructured":"Iwaya C.; Nomiyama T.; Komatsu S.; Kawanami T.; Tsutsumi Y.; Hamaguchi Y.; Horikawa T.; Yoshinaga Y.; Yamashita S.; Tanaka T.; Terawaki Y.; Tanabe M.; Nabeshima K.; Iwasaki A.; Yanase T.; Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation. Endocrinology 2017,158(12),4218-4232","journal-title":"Endocrinology"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2337\/db13-1169","volume":"63","author":"Nomiyama T.","year":"2014","unstructured":"Nomiyama T.; Kawanami T.; Irie S.; Hamaguchi Y.; Terawaki Y.; Murase K.; Tsutsumi Y.; Nagaishi R.; Tanabe M.; Morinaga H.; Tanaka T.; Mizoguchi M.; Nabeshima K.; Tanaka M.; Yanase T.; Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes 2014,63(11),3891-3905","journal-title":"Diabetes"},{"key":"ref=141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139709","volume":"10","author":"Tsutsumi Y.","year":"2015","unstructured":"Tsutsumi Y.; Nomiyama T.; Kawanami T.; Hamaguchi Y.; Terawaki Y.; Tanaka T.; Murase K.; Motonaga R.; Tanabe M.; Yanase T.; Combined treatment with exendin-4 and metformin attenuates prostate cancer growth. PLoS One 2015,10(10)","journal-title":"PLoS One"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"Elashoff M.","year":"2011","unstructured":"Elashoff M.; Matveyenko A.V.; Gier B.; Elashoff R.; Butler P.C.; Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011,141(1),150-156","journal-title":"Gastroenterology"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"Scirica B.M.","year":"2013","unstructured":"Scirica B.M.; Bhatt D.L.; Braunwald E.; Steg P.G.; Davidson J.; Hirshberg B.; Ohman P.; Frederich R.; Wiviott S.D.; Hoffman E.B.; Cavender M.A.; Udell J.A.; Desai N.R.; Mosenzon O.; McGuire D.K.; Ray K.K.; Leiter L.A.; Raz I.; Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med SAVOR-TIMI 53 Steering Committee and Investigators2013,369(14),1317-1326","journal-title":"N Engl J Med"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"White W.B.","year":"2013","unstructured":"White W.B.; Cannon C.P.; Heller S.R.; Nissen S.E.; Bergenstal R.M.; Bakris G.L.; Perez A.T.; Fleck P.R.; Mehta C.R.; Kupfer S.; Wilson C.; Cushman W.C.; Zannad F.; Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med EXAMINE Investigators2013,369(14),1327-1335","journal-title":"N Engl J Med"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","volume":"306","author":"Zhao H.","year":"2014","unstructured":"Zhao H.; Wei R.; Wang L.; Tian Q.; Tao M.; Ke J.; Liu Y.; Hou W.; Zhang L.; Yang J.; Hong T.; Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Am J Physiol Endocrinol Metab 2014,306(12),E1431-E1441","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1530\/EC-17-0294","volume":"6","author":"Kosowska A.","year":"2017","unstructured":"Kosowska A.; Gallego-Colon E.; Garczorz W.; K\u0142ych-Ratuszny A.; Aghdam M.R.F.; Woz N.M.; Witek A.; Wr\u00f3blewska-Czech A.; Cygal A.; Wojnar J.; Francuz T.; Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells. Endocr Connect 2017,6(8),856-865","journal-title":"Endocr Connect"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2337\/dc11-1596","volume":"35","author":"Tseng P.H.","year":"2012","unstructured":"Tseng P.H.; Lee Y.C.; Chiu H.M.; Chen C.C.; Liao W.C.; Tu C.H.; Yang W.S.; Wu M.S.; Association of diabetes and HbA1c levels with gastrointestinal manifestations. Diabetes Care 2012,35(5),1053-1060","journal-title":"Diabetes Care"},{"key":"ref=148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187434","volume":"12","author":"Chen Y.C.","year":"2017","unstructured":"Chen Y.C.; Ho C.C.; Yi C.H.; Liu X.Z.; Cheng T.T.; Lam C.F.; Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats. PLoS One 2017,12(11)","journal-title":"PLoS One"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T18:47:53Z","timestamp":1664650073000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175547\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":148,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,12,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201816666191010145029","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}